[Stent-assisted Recanalization of Femoropopliteal Arterial Occlusive Disease. Influence of Stent Design on Patency Rates]

Overview

Journal Radiologe

Specialty Radiology

Date 2016 Feb 5

PMID 26842999

Authors

M Treitl

M F Reiser

K M Treitl

Affiliations

Soon will be listed here.

Abstract

Background: Despite enormous technical progress the results of endovascular treatment of the femoropopliteal vasculature are unsatisfactory and its role is still controversially discussed. In the past decade numerous new stent designs have come onto the market but it is unclear whether they have benefits with respect to patency rates.

Objectives: Comparison of published data on patency rates and target lesion revascularization rates after use of different stent designs in the femoropopliteal vasculature.

Material And Methods: Analysis of 25 published studies and registries from 2006 to 2015 for classical open-cell stents, interwoven stents and partially or fully covered stents.

Results And Conclusion: The published data are heterogeneous and comparative studies for different stent designs are completely missing. Over the past decade the patency rates after femoropopliteal stenting could be improved. According to available data stenting of short lesions < 5 cm does not show any benefit compared to isolated balloon angioplasty. Primary stenting is now recommended for intermediate and longer lesions > 6.4 cm. Due to the heterogeneity of published data a clear benefit for a specific stent design is not obvious; however, data for interwoven stents are promising and show a tendency towards improved patency, at least for certain lesions. Randomized controlled comparative trials are needed to confirm this result.

References

Saxon R, Chervu A, Jones P, Bajwa T, Gable D, Soukas P . Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery.... J Vasc Interv Radiol. 2013; 24(2):165-73. DOI: 10.1016/j.jvir.2012.10.004. View

Krankenberg H, Schluter M, Steinkamp H, Burgelin K, Scheinert D, Schulte K . Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007; 116(3):285-92. DOI: 10.1161/CIRCULATIONAHA.107.689141. View

Tsai T . The superficial femoral artery conundrum: so close, yet so far away!. JACC Cardiovasc Interv. 2014; 7(7):799-800. DOI: 10.1016/j.jcin.2014.05.003. View

Zhang L, Bao J, Zhao Z, Lu Q, Zhou J, Jing Z . Effectiveness of Viabahn in the Treatment of Superficial Femoral Artery Occlusive Disease: A Systematic Review and Meta-analysis. J Endovasc Ther. 2015; 22(4):495-505. DOI: 10.1177/1526602815588274. View

Shackles C, Rundback J, Herman K, David Y, Barkarma R . Above and below knee femoropopliteal VIABAHN®. Catheter Cardiovasc Interv. 2014; 85(5):859-67. DOI: 10.1002/ccd.25666. View

Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W . Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006; 354(18):1879-88. DOI: 10.1056/NEJMoa051303. View

Dumantepe M, Seren M, Fazliogullari O, Ayoglu U, Teymen B . Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: Midterm results. Vascular. 2015; 29(5):711-719. DOI: 10.1177/1708538114568884. View

Parthipun A, Diamantopoulos A, Kitrou P, Padayachee S, Karunanithy N, Ahmed I . Use of a New Hybrid Heparin-Bonded Nitinol Ring Stent in the Popliteal Artery: Procedural and Mid-term Clinical and Anatomical Outcomes. Cardiovasc Intervent Radiol. 2015; 38(4):846-54. DOI: 10.1007/s00270-015-1113-4. View

Bosiers M, Torsello G, Gissler H, Ruef J, Muller-Hulsbeck S, Jahnke T . Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009; 16(3):261-9. DOI: 10.1583/08-2676.1. View

10.

Chan Y, Cheng S, Cheung G . Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease. J Vasc Surg. 2015; 62(5):1201-9. DOI: 10.1016/j.jvs.2015.05.030. View

11.

Brescia A, Wickers B, Correa J, Smeds M, Jacobs D . Stenting of femoropopliteal lesions using interwoven nitinol stents. J Vasc Surg. 2015; 61(6):1472-8. DOI: 10.1016/j.jvs.2015.01.030. View

12.

R Leon Jr L, Dieter R, Gadd C, Ranellone E, Mills Sr J, Montero-Baker M . Preliminary results of the initial United States experience with the Supera woven nitinol stent in the popliteal artery. J Vasc Surg. 2013; 57(4):1014-22. DOI: 10.1016/j.jvs.2012.10.093. View

13.

Garcia L, Jaff M, Metzger C, Sedillo G, Pershad A, Zidar F . Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial. Circ Cardiovasc Interv. 2015; 8(5). DOI: 10.1161/CIRCINTERVENTIONS.113.000937. View

14.

Bosiers M, Deloose K, Callaert J, Keirse K, Verbist J, Hendriks J . 4-French-compatible endovascular material is safe and effective in the treatment of femoropopliteal occlusive disease: results of the 4-EVER trial. J Endovasc Ther. 2013; 20(6):746-56. DOI: 10.1583/13-4437MR.1. View

15.

Chalmers N, Walker P, Belli A, Thorpe A, Sidhu P, Robinson G . Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol. 2012; 36(2):353-61. DOI: 10.1007/s00270-012-0492-z. View

16.

Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D . Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery. JACC Cardiovasc Interv. 2014; 7(7):792-8. DOI: 10.1016/j.jcin.2014.01.168. View

17.

Geraghty P, Mewissen M, Jaff M, Ansel G . Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013; 58(2):386-95.e4. DOI: 10.1016/j.jvs.2013.01.050. View

18.

Piorkowski M, Freitas B, Steiner S, Botsios S, Bausback Y, Scheinert D . Twelve-month experience with the GORE® TIGRIS® Vascular Stent in the superficial femoral and popliteal arteries. J Cardiovasc Surg (Torino). 2014; 56(1):89-95. View

19.

Mcquade K, Gable D, Pearl G, Theune B, Black S . Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg. 2010; 52(3):584-90. DOI: 10.1016/j.jvs.2010.03.071. View

20.

Ullery B, Tran K, Itoga N, Casey K, Dalman R, Lee J . Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease. J Vasc Surg. 2015; 61(6):1479-88. DOI: 10.1016/j.jvs.2014.12.062. View